Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06829472 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 17, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Conditioning regimen with melphalan-busulfan and fludarabine (MBF) achieved low relapse rate in patients with acute myeloid leukemia (AML) and myelodysplasia syndrome (MDS). In our previous retrospective study, we demonstrated that melphalan dose at 100 or 140mg/m2 had similar incidence of relapse but it might had lower toxicities. In this prospective randomize study, we aim to compare the transplantation outcome in adult patients with AML/MDS receiving either MBF with 100 or 140 mg/m2 melphalan.
Trial Details
NCT Number NCT06829472
Lead Sponsor Shanghai Jiao Tong University School of Medicine
Collaborators: Shanghai Clinical Research Center
Conditions
(from sponsor)		 Toxicities, Survivorship
Related terms Leukemia, Myeloid, Acute
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov